Overview


According to FutureWise analysis, the market for Acute Myeloid Leukemia Treatment  is expected to grow at a CAGR of 10.37% over the forecast period of 2023-2031.

Acute myeloid leukemia is a blood cancer and bone marrow cancer. It affects a group of white blood cells called myeloid cells because they are formed in the bone marrow. "Acute" means it develops and advances quickly and requires immediate treatment. Ayurveda helps treat this disease by reducing the abnormal growth of immature cells that appears in the bone marrow. Ayurveda delivers holistic solutions with natural herbs and safe treatment. It helps control the regrowth of mature cells into the bloodstream. Generally, the bone marrow produces blood stem cells that evolve into mature blood cells over a period. A blood stem cell may develop into a myeloid or lymphoid stem cell.
Chemotherapy is the use of drugs to stop or slow down the growth and longevity of cancer cells. Chemotherapy targets growing cells, interfering with their ability to divide or multiply. Because most of an adult's normal body cells are not actively growing, they are not as affected as much by chemotherapy as the cancer cells. However, the normal cells in the bone marrow (where the blood cells are produced), hair follicles, and the gastrointestinal (GI) tract lining are all growing. Outcomes of chemotherapy on these and other normal tissues cause side effects during treatment, including hair loss, anemia (lowered red blood cell count), nausea, increased risk of infection (reduced white blood cell count), and bleeding (decreased platelet count).

FutureWise Market Research has published a report that provides an insightful analysis acute myeloid leukemia treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, acute myeloid leukemia treatment market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.
  • Johnson and Johnson
  • Pfizer Inc.
  • Celgene Corporation
  • Ambit Biosciences Corporation
  • Cyclacel Pharmaceuticals Inc.
  • Novartis AG
  • Sanofi
  • Bristol Myers Squibb
  • Verastem, Inc.
  • Genezyme Corporation
  • Neomed Management AS
  • Sunesis Pharmaceuticals Inc.
  • GalaxoSmithKline plc
  • Alcami
  • BASF

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Acute Myeloid Leukemia Treatment Market:

  • In January 2022- To treat acute myeloid leukemia (AML), Oncolyze announced the receipt of FDA Orphan Drug Designation for OM-301. 
  • In December 2021- the European Commission granted Orphan Drug Designation to SNDX-5613, a highly selective oral menin inhibitor, to treat acute myeloid leukemia (AML) developed by Syndax Pharmaceuticals Inc.

The rising prevalence of acute myeloid leukemia (AML) is expected to propel the market's growth. The geriatric population, especially in developed countries, is contributing to the higher incidence of AML, as the risk of this disease tends to increase with age. Growing awareness among healthcare experts and the general public about early detection and diagnosis of AML has improved patient outcomes and increased demand for effective treatments. Moreover, collaborations between academic institutions, research organizations, and pharmaceutical industries have enabled knowledge sharing and accelerated drug discovery processes. Additionally, the approval and commercialization of novel therapies, such as targeted therapies and immunotherapies, have expanded patient treatment options, further driving market growth. According to the American Cancer Society, it is expected that there will be 60,650 new leukemia cancer cases, of which 24,000 are anticipated to die in 2022 in the Unites States. In addition, as per the same source, 20,050 new cases of acute myeloid leukemia are expected in 2022 in the US. It will lead to advanced adoption of AML treatments. Furthermore, the lack of skilled healthcare professionals and several other factors are expected to restrain the growth of the market during the forecast period. Limited access to advances healthcare facilities, particularly in developing regions, hinders the timely diagnosis and optimal treatment for acute myeloid leukemia patients. Moreover, the high cost of AML therapies, including targeted treatment and immunotherapies, may restrict their affordability and accessibility for a significant part of the patient population. Additionally, strict regulatory practices for drug approvals and the lengthy process of clinical trials may delay the implementation of new therapies into the market.

By Disease Type

  • Myeloblastic
  • Promyeloctic
  • Myelomonocytic
  • Monocytic
  • Erythroleukemia
  • Megakaryocytic

By Treatment

  • Chemotherapy
    • Induction
    • Post Remission
  • Hematopoietic Stem Cell Transplantation

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The growing prevalence of acute myeloid leukemia cases in the United States is expected to propel the market growth in the region. For instance, in 2021 as per the American Society of Clinical Oncology, acute myeloid leukemia is a scarce malignancy that registers for around 1% of all cancers. Acute myeloid leukemia is the second the most dominant type of leukemia in adults and children. Therefore, the rising incidence of acute myeloid leukemia in the Unites States will lead to higher treatment adoption for this disease, therefore expected to drive the growth of the market in North America.
  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Acute Myeloid Leukemia Treatment Market By Disease Type, By Treatment, By Distribution Channel and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Acute Myeloid Leukemia Treatment Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Myeloid Leukemia Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Acute Myeloid Leukemia Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Acute Myeloid Leukemia Treatment Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Myeloblastic
        2. Promyeloctic
        3. Myelomonocytic
        4. Monocytic
        5. Erythroleukemia
        6. Megakaryocytic

  • 8.   Acute Myeloid Leukemia Treatment Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Chemotherapy
         1.1. Induction
         1.2. Post Remission
        2. Hematopoietic Stem Cell Transplantation

  • 9.   Acute Myeloid Leukemia Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy

  • 10.   North America Acute Myeloid Leukemia Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Acute Myeloid Leukemia Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Acute Myeloid Leukemia Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Acute Myeloid Leukemia Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Acute Myeloid Leukemia Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Disease Types Offered and Financial Layouts)

    •   1. Johnson and Johnson
         1.1. Company Overview
         1.2. Disease Type Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pfizer Inc.
         2.1. Company Overview
         2.2. Disease Type Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Celgene Corporation
         3.1. Company Overview
         3.2. Disease Type Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Ambit Biosciences Corporation
         4.1. Company Overview
         4.2. Disease Type Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Cyclacel Pharmaceuticals Inc.
         5.1. Company Overview
         5.2. Disease Type Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis AG
         6.1. Company Overview
         6.2. Disease Type Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sanofi
         7.1. Company Overview
         7.2. Disease Type Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Bristol Myers Squibb
         8.1. Company Overview
         8.2. Disease Type Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Verastem, Inc.
         9.1. Company Overview
         9.2. Disease Type Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Genezyme Corporation
         10.1. Company Overview
         10.2. Disease Type Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Neomed Management AS
         11.1. Company Overview
         11.2. Disease Type Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Sunesis Pharmaceuticals Inc.
         12.1. Company Overview
         12.2. Disease Type Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. GalaxoSmithKline plc
         13.1. Company Overview
         13.2. Disease Type Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Alcami
         14.1. Company Overview
         14.2. Disease Type Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. BASF
         15.1. Company Overview
         15.2. Disease Type Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11